

**INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED
AND ITS SUBSIDIARIES**

**REVIEW REPORT AND INTERIM FINANCIAL INFORMATION
FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2023**

INDEPENDENT AUDITOR'S REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To The Shareholders and Board of Directors of
Intermedical Care and Lab Hospital Public Company Limited

I have reviewed the accompanying consolidated statements of financial position of Intermedical Care and Lab Hospital Public Company Limited and its subsidiaries as at September 30, 2023, and the related consolidated statement of comprehensive income for the three-month and nine-month periods then ended, consolidated statement of changes in shareholders' equity and consolidated statement of cash flows for the nine-month period then ended, and the condensed notes to the interim financial statements and I have also reviewed the separate financial information of Intermedical Care and Lab Hospital Public Company Limited for the same periods. Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard No. 34 "Interim Financial Reporting". My responsibility is to express a conclusion on this interim financial information based on my review.

SCOPE OF REVIEW

I conducted my review in accordance Thai Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

CONCLUSION

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard No. 34 "Interim Financial Reporting".

EMPHASIS OF MATTERS

As discussed in Note 4 to the interim financial statement, the Subsidiary acquired share of Mahaesak Hospital Company Limited. The acquisition transaction completion date is on May 31, 2023 (at the acquisition date). The acquisition qualifies for treatment as a business combination in accordance with TFRS 3 Business Combinations, which requires that the assets acquired and liabilities assumed be recorded at their fair values, together with goodwill, if any. The Subsidiary has engaged an independent appraisers to determine the fair values of the assets acquired and liabilities assumed. At the present, the fair value exercise has not been completed. Accordingly, the Subsidiary recognized the provisional amount of the net assets acquired based on book values at the acquisition date and record the excess of the acquisition cost over the fair value of the net assets acquired amounted Baht 850.30 million as goodwill. However, the Subsidiary is continuing their review of the identifiable assets and liabilities, as permitted under TFRS 3 during a measurement period of not exceed 1 year from the acquisition date. If new information is obtained about facts and circumstances that existed at the acquisition date which would require further adjustment to the values initially recognized, then such adjustments would be recorded when this information becomes available.

(Miss Soraya Tintasuwan)

Certified Public Accountant

Registration No. 8658

Dharmniti Auditing Company Limited

Bangkok, Thailand

November 13, 2023

"UNAUDITED"

"REVIEWED"

- 3 -

INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED

AND ITS SUBSIDIARIES

STATEMENT OF FINANCIAL POSITION

AS AT SEPTEMBER 30, 2023

		ASSETS			
		Baht			
		Consolidated financial statements		Separate financial statements	
		As at September	As at December	As at September	As at December
Notes		30, 2023	31, 2022	30, 2023	31, 2022
Current assets					
Cash and cash equivalents	6	43,559,377.66	153,218,188.78	5,940,573.54	96,618,163.15
Trade and other current receivables	5, 7	56,725,922.91	26,611,092.24	47,865,995.47	35,264,885.55
Current contract assets	8	431,893,075.11	375,298,037.91	30,938,515.66	37,090,634.96
Short-term loans to subsidiary	5	-	-	40,000,000.00	-
Inventories	9	24,739,432.80	14,390,639.81	7,477,733.75	2,897,869.04
Other current assets	10	12,237,192.03	10,522,064.85	7,710,717.50	8,791,110.85
Total current assets		569,155,000.51	580,040,023.59	139,933,535.92	180,662,663.55
Non-current assets					
Restricted bank deposits	26.7	12,613,642.82	10,866,050.00	6,866,050.00	6,866,050.00
Investments in subsidiaries	11	-	-	978,985,600.00	164,799,900.00
Property, plant and equipment	12	240,482,341.42	159,044,206.47	120,480,558.91	128,790,343.18
Right-of-use assets	13	157,026,508.38	165,063,609.32	9,126,570.13	12,133,592.67
Goodwill	4	966,559,551.44	116,258,349.73	-	-
Other intangible assets	14	46,647,233.92	48,725,896.43	2,856,795.52	3,743,627.51
Deferred tax assets	15	8,527,326.08	5,273,135.77	1,632,309.29	1,348,433.96
Other non-current assets	26.2	44,521,583.75	9,194,865.00	68,965.00	68,965.00
Total non-current assets		1,476,378,187.81	514,426,112.72	1,120,016,848.85	317,750,912.32
Total assets		2,045,533,188.32	1,094,466,136.31	1,259,950,384.77	498,413,575.87

Notes to the interim financial statements form an integral part of these interim financial statements.

"UNAUDITED"

"REVIEWED"

- 4 -

**INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED
AND ITS SUBSIDIARIES**

STATEMENT OF FINANCIAL POSITION (CONT.)

AS AT SEPTEMBER 30, 2023

LIABILITIES AND SHAREHOLDERS' EQUITY

		Baht			
		Consolidated financial statements		Separate financial statements	
		As at September	As at December	As at September	As at December
Notes		30, 2023	31, 2022	30, 2023	31, 2022
Current liabilities					
Trade and other current payables	5, 16	151,920,268.23	45,948,684.18	19,687,809.90	15,919,447.71
Short-term loans from subsidiary		-	-	20,000,000.00	-
Current Portion					
Long-term loans from financial institutions	17	105,000,000.00	-	105,000,000.00	-
Leases liabilities	18	8,675,939.17	8,671,351.36	5,045,116.91	5,566,682.66
Corporate income tax payables		12,773,978.38	25,768,122.09	-	-
Other current provisions		-	1,658,911.91	-	-
Other current liabilities		757,528.67	1,550,546.32	453,218.21	1,189,031.19
Total current liabilities		279,127,714.45	83,597,615.86	150,186,145.02	22,675,161.56
Non - current liabilities					
Long-term loans from financial institutions	17	693,000,000.00	-	693,000,000.00	-
Leases liabilities	18	160,479,697.15	163,913,279.69	2,096,405.06	5,151,361.07
Employee benefit obligations	19	16,330,617.22	6,966,147.99	6,910,435.99	5,585,970.99
Deferred tax liabilities	15	5,586,893.94	5,577,066.21	-	-
Other non-current provisions	20	36,801,926.77	-	-	-
Deferred subsidies		3,788,602.11	4,236,989.02	-	-
Total non-current liabilities		915,987,737.19	180,693,482.91	702,006,841.05	10,737,332.06
Total liabilities		1,195,115,451.64	264,291,098.77	852,192,986.07	33,412,493.62

Notes to the interim financial statements form an integral part of these interim financial statements.

"UNAUDITED"

"REVIEWED"

- 5 -

INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED

AND ITS SUBSIDIARIES

STATEMENT OF FINANCIAL POSITION (CONT.)

AS AT SEPTEMBER 30, 2023

LIABILITIES AND SHAREHOLDERS' EQUITY (CONT.)

		Baht			
		Consolidated financial statements		Separate financial statements	
		As at September	As at December	As at September	As at December
Notes		30, 2023	31, 2022	30, 2023	31, 2022
Shareholders' equity					
Share capital					
Authorized share capital					
	215,000,000 ordinary shares, Baht 0.50 par value	107,500,000.00	107,500,000.00	107,500,000.00	107,500,000.00
Issued and fully paid-up					
	215,000,000 ordinary shares, Baht 0.50 par value	107,500,000.00	107,500,000.00	107,500,000.00	107,500,000.00
	Premium on ordinary shares	262,690,733.19	262,690,733.19	262,690,733.19	262,690,733.19
	Premium on treasury shares	21 558.00	-	558.00	-
Retained earnings					
Appropriated					
	Legal reserve	10,750,000.00	10,750,000.00	10,750,000.00	10,750,000.00
	Treasury shares reserve	21 13,262,888.00	13,286,810.00	13,262,888.00	13,286,810.00
	Unappropriated	460,383,020.66	449,039,408.40	26,816,107.51	84,060,349.06
	Treasury shares	21 (13,262,888.00)	(13,286,810.00)	(13,262,888.00)	(13,286,810.00)
	Total attributable to company's shareholders	841,324,311.85	829,980,141.59	407,757,398.70	465,001,082.25
	Non-controlling interests	9,093,424.83	194,895.95	-	-
	Total shareholders' equity	850,417,736.68	830,175,037.54	407,757,398.70	465,001,082.25
	Total liabilities and shareholders' equity	2,045,533,188.32	1,094,466,136.31	1,259,950,384.77	498,413,575.87

Notes to the interim financial statements form an integral part of these interim financial statements.

"REVIEWED"

INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED
AND ITS SUBSIDIARIES

FOR THE THREE-MONTH PERIOD ENDED SEPTEMBER 30, 2023

Notes to the interim financial statements form an integral part of these interim financial statements.

"REVIEWED"

INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED
AND ITS SUBSIDIARIES

FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2023

Notes to the interim financial statements form an integral part of these interim financial statements.

"UNAUDITED"

"REVIEWED"

- 8 -

INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2023

		Baht									
		Consolidated financial statements									
		Equity attributable to owners of the parent							Non-controlling interests	Total shareholders' equity	
		Issued and paid-up share capital	Premium on ordinary shares	Premium on treasury shares	Retained earnings		Treasury shares	Total share holders' equity of the parent			
Notes					Appropriated to legal reserve	Appropriated to treasury shares reserve	Unappropriated				
	Balance as at January 1, 2023	107,500,000.00	262,690,733.19	-	10,750,000.00	13,286,810.00	449,039,408.40	(13,286,810.00)	829,980,141.59	194,895.95	830,175,037.54
	Non-controlling interests in the subsidiaries										
	Increase from business acquisition	4	-	-	-	-	-	-	-	8,012,285.00	8,012,285.00
	Dividend	22	-	-	-	-	(29,861,146.00)	-	(29,861,146.00)	-	(29,861,146.00)
	Reissuance of treasury shares	21	-	-	558.00	-	-	23,922.00	24,480.00	-	24,480.00
	Appropriated - treasury shares reserve	21	-	-	-	(23,922.00)	23,922.00	-	-	-	-
	Total comprehensive income for the period										
	Profit for the period		-	-	-	-	41,180,836.26	-	41,180,836.26	886,243.88	42,067,080.14
	Balance as at September 30, 2023		107,500,000.00	262,690,733.19	558.00	10,750,000.00	13,262,888.00	460,383,020.66	(13,262,888.00)	841,324,311.85	850,417,736.68
	Balance as at January 1, 2022 - as restated		107,500,000.00	262,690,733.19	-	10,750,000.00	13,286,810.00	463,454,996.25	(13,286,810.00)	844,395,729.44	-
	Non-controlling interests from set up new subsidiaries		-	-	-	-	-	-	-	200,100.00	200,100.00
	Dividend		-	-	-	-	(192,599,910.00)	-	(192,599,910.00)	-	(192,599,910.00)
	Total comprehensive income for the period										
	Profit for the period		-	-	-	-	219,890,640.92	-	219,890,640.92	(5,244.63)	219,885,396.29
	Other comprehensive income - net of income tax										
	Actuarial gain on defined employee benefit plans		-	-	-	-	5,074,334.80	-	5,074,334.80	-	5,074,334.80
	Balance as at September 30, 2022		107,500,000.00	262,690,733.19	-	10,750,000.00	13,286,810.00	495,820,061.97	(13,286,810.00)	876,760,795.16	194,855.37
											876,955,650.53

Notes to the interim financial statements form an integral part of these interim financial statements.

"UNAUDITED"

"REVIEWED"

- 9 -

INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CONT.)

FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2023

		Baht							
		Separate financial statements							
Notes		Issued and paid-up share capital	Premium on ordinary shares	Premium on ordinary shares	Retained earnings			Treasury shares	Total shareholders'
				Appropriated to legal reserve	Appropriated to treasury shares reserve	Unappropriated		equity	
		107,500,000.00	262,690,733.19	-	10,750,000.00	13,286,810.00	84,060,349.06	(13,286,810.00)	465,001,082.25
	22	-	-	-	-	-	(29,861,146.00)	-	(29,861,146.00)
	21	-	-	558.00	-	-	-	23,922.00	24,480.00
	21	-	-	-	-	(23,922.00)	23,922.00	-	-
Total comprehensive income for the period									
		-	-	-	-	-	(27,407,017.55)	-	(27,407,017.55)
		107,500,000.00	262,690,733.19	558.00	10,750,000.00	13,262,888.00	26,816,107.51	(13,262,888.00)	407,757,398.70
		107,500,000.00	262,690,733.19	-	10,750,000.00	13,286,810.00	267,525,884.80	(13,286,810.00)	648,466,617.99
		-	-	-	-	-	(192,599,910.00)	-	(192,599,910.00)
Total comprehensive income for the period									
		-	-	-	-	-	9,028,767.58	-	9,028,767.58
Other comprehensive income - net of income tax									
		-	-	-	-	-	4,014,899.20	-	4,014,899.20
		107,500,000.00	262,690,733.19	-	10,750,000.00	13,286,810.00	87,969,641.58	(13,286,810.00)	468,910,374.77

Notes to the interim financial statements form an integral part of these interim financial statements.

"UNAUDITED"

"REVIEWED"

- 10 -

INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED

AND ITS SUBSIDIARIES

STATEMENT OF CASH FLOWS

FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2023

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
<u>Cash flows from operating activities</u>				
Profit (loss) before (income) tax expenses	60,015,183.61	271,920,362.25	(27,690,892.88)	11,787,577.54
Adjustments to profit (loss) before (income) tax expenses				
to cash provided by (used in) from operations:				
Expected credit losses (reversal)	1,534,102.83	(286,043.97)	151,125.77	(405,007.63)
Depreciation and amortization	30,332,407.67	26,878,114.68	13,198,483.45	15,571,069.98
Gain from write-off assets	-	(368,278.58)	-	(527,911.69)
Employee benefit expenses	1,529,593.32	1,238,861.00	1,324,465.00	1,044,135.00
Interest expenses	17,948,103.47	8,060,168.86	14,940,494.52	608,282.31
Interest income	(832,092.35)	(326,718.67)	(1,541,985.20)	(249,892.98)
Profit from operations before changes in operating assets				
and liabilities	110,527,298.55	307,116,465.57	381,690.66	27,828,252.53
Changes in operating assets - (Increase) Decrease				
Trade and other current receivables	(20,563,633.07)	14,368,499.29	(12,636,736.17)	5,011,596.57
Current contract assets	(35,358,332.66)	(185,903,906.24)	6,201,003.34	12,719,244.05
Inventories	(6,854,721.07)	(1,244,184.02)	(4,579,864.71)	2,416,071.64
Other current assets	(986,743.20)	2,926,550.02	1,080,393.35	4,844,624.00
Other non - current assets	(34,319,472.71)	(1,858,600.00)	-	-
Changes in operating liabilities - Increase (Decrease)				
Trade and other current payables	29,575,884.94	(9,324,461.04)	3,673,964.93	(11,249,509.69)
Other current provisions	(1,658,911.91)	(300,000.00)	-	-
Other current liabilities	(793,017.65)	563,554.48	(735,812.98)	577,088.08
Other non-current provisions	-	(2,033,188.85)	-	(2,033,188.85)
Employee benefit paid	-	(114,336.00)	-	(114,336.00)
Deferred subsidies	(448,386.91)	(448,386.91)	-	-
Cash generated (paid) from operation	39,119,964.31	123,748,006.30	(6,615,361.58)	39,999,842.33
Cash paid for income tax	(32,468,380.25)	(90,908,229.47)	-	(2,805,249.25)
Net cash provided by (used in) operating activities	6,651,584.06	32,839,776.83	(6,615,361.58)	37,194,593.08

Notes to the interim financial statements form an integral part of these interim financial statements.

"UNAUDITED"

"REVIEWED"

- 11 -

**INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED
AND ITS SUBSIDIARIES**

STATEMENT OF CASH FLOWS (CONT.)

FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2023

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
<u>Cash flows from investing activities</u>				
Cash paid for purchase of investments in subsidiaries	-	-	-	(799,900.00)
Cash received from short-term loans to subsidiaries	-	-	-	2,000,000.00
Cash paid for short-term loans to subsidiaries	-	-	(40,000,000.00)	-
Cash paid in business acquisition	(842,545,997.17)	-	-	-
Cash paid for purchase of investments	-	-	(814,185,700.00)	-
Cash paid for purchase of property, plant and equipment	(19,527,641.27)	(14,742,348.43)	(342,144.65)	(3,704,629.38)
Cash received from sale of assets	143,157.11	1,951,258.88	-	1,880,158.88
Cash paid for purchase of intangible assets	(402,492.00)	(535,070.00)	-	(342,400.00)
Cash received from deposits of right-of-uses assets	-	895,000.00	-	895,000.00
Cash paid for deposits of right-of-uses assets	(28,500.00)	(1,145,000.00)	-	(1,145,000.00)
Cash received from interest	832,092.35	326,718.67	1,377,601.64	249,892.98
Cash received from dividend of	-	-	-	192,598,395.00
Net cash provided by (used in) investing activities	(861,529,380.98)	(13,249,440.88)	(853,150,243.01)	191,631,517.48
<u>Cash flows from financing activities</u>				
Cash received from investments in subsidiaries from non-controlling interests	-	200,100.00	-	-
Cash received from short-term loans from subsidiaries	-	-	20,000,000.00	-
Cash received long-term loans from financial institutions	800,000,000.00	-	800,000,000.00	-
Cash paid for financial cost of long-term loans	(2,000,000.00)	-	(2,000,000.00)	-
Cash paid for long-term loans from financial institutions	-	(6,072,468.78)	-	(6,072,468.78)
Cash paid for lease liabilities	(4,996,544.73)	(5,372,418.79)	(4,229,221.76)	(5,998,692.47)
Cash received from reissuance of treasury shares	24,480.00	-	24,480.00	-
Cash paid for dividend	(29,861,146.00)	(192,599,910.00)	(29,861,146.00)	(192,599,910.00)
Cash paid for interest	(17,948,103.47)	(8,060,168.86)	(14,846,097.26)	(608,282.31)
Cash received from share of non-controlling interests	300.00	-	-	-
Net cash provided by (used in) financing activities	745,218,985.80	(211,904,866.43)	769,088,014.98	(205,279,353.56)
Net increase (decrease) in cash and cash equivalents	(109,658,811.12)	(192,314,530.48)	(90,677,589.61)	23,546,757.00
Cash and cash equivalents at beginning of the period	153,218,188.78	330,115,813.86	96,618,163.15	83,526,443.38
Cash and cash equivalents at end of the period	43,559,377.66	137,801,283.38	5,940,573.54	107,073,200.38
<u>Additional disclosure items to cash flows statements</u>				
Non-cash transaction :				
Increase in right-of-uses assets	1,596,050.00	3,541,321.26	652,700.00	3,541,321.26
Purchase of shares that have not yet been paid	34,530,444.44	-	-	-

Notes to the interim financial statements form an integral part of these interim financial statements.

**INTERMADICAL CARE AND LAB HOSPITAL PUBLIC COMPANY LIMITED
AND ITS SUBSIDIARIES
NOTES TO THE INTERIM FINANCIAL STATEMENTS
SEPTEMBER 30, 2023**

1. GENERAL INFORMATION

Intermadical Care and Lab Hospital Public Company Limited (“the Company”) was registered as a juristic person under the Civil and Commercial Code on July 8, 1996 and registered as a public limited company on June 21, 2018. The Company had sold the capital increase ordinary shares for the public offering and the Company’s ordinary shares had started trading on the Market for Alternative Investment (MAI) on December 26, 2019.

The Company is principally engaged in specialty medical hospital, occupational medicine with the registered address as follows:

Head office : 442 Bang Waek Road Bang Waek Sub-district, Pha-si-cha-roen District, Bangkok

Branch 1 : 444 Bang Waek Road Bang Waek Sub-district, Pha-si-cha-roen District, Bangkok

Branch 2 : 126/11-13 moo.3 Nong talueeng, Phanthong, Chonburi

Branch 3 : 9/61-62 moo.19 Khlong Nueng, Klong Luang, Pathumthani

Branch 4 : 60/29-30 moo.3 Map Yang Phon, Pluak Daeng, Rayong

Branch 5 : 96/11 moo.6 Khon Hua Lo, Mueang Chonburi , Chonburi

Accufas Lab Center Co., Ltd. Which is a subsidiary, established as a limited company under Thai civil and commercial Act, registration number 0105540029193 on March 20, 1997. The Subsidiary’s head office is located at 442 Bang Waek Road, Bang Waek sub-district, Pha-si-cha-roen district, Bangkok. The main business is Hospital (IMH Thonburi Hospital).

Suksawat medical Co., Ltd. Which is a subsidiary, established as a limited company under Thai civil and commercial Act, registration number 0105551104540 on September 15, 2008. The Subsidiary’s office is located at 146 Suksawat road, Bangprakok sub-district, Ratburana district, Bangkok. The main business is operated a hospital business. In 2022, it had been transferred its hospital business to Accufas Lab Center Co.,Ltd. However, the Company’s management is in the process of seeking the suitable business for further activities.

IMH Bearing Hospital Co., Ltd. Which is a subsidiary, established as a limited company under Thai civil and commercial Act, registration number 0105565130203 on August 11, 2022. The Subsidiary’s office is located at 442 Bang Waek Road, Bang Waek sub-district, Pha-si-cha-roen district, Bangkok. The main business is Hospital (Pre-operating Stage).

IMH Silom Hospital Co., Ltd. Which is a subsidiary, established as a limited company under Thai civil and commercial Act, registration number 0105566021751 on January 31, 2023. The Subsidiary's office is located at 442 Bang Waek Road, Bang Waek sub-district, Pha-si-cha-roen district, Bangkok. The main business is Hospital.

Mahaesak Hospital Co., Ltd. Which is a subsidiary, established as a limited company under Thai civil and commercial Act, registration number 0105518007255 on July 21, 1975. The Subsidiary's office is located at 46/7-9 Mahaesak Road, Suriyawong sub-district, Bang Rak district, Bangkok. The main business is Hospital. In 2023, it had been transferred its hospital business to IMH Silom Hospital Co., Ltd. However, the Company's management is in the process of seeking the suitable business for further activities.

2. BASIS FOR PREPARATION OF INTERIM FINANCIAL STATEMENTS

2.1 Basis for the preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No.34 "Interim Financial Reporting", and the requirements of the Securities and Exchange Commission (SEC). The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with the financial statements for the year ended December 31, 2022.

The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the financial statements in Thai language version.

2.2 Basis of consolidated interim financial statements preparation

- a) The consolidated interim financial statements include the interim financial statements of Intermedical Care and Lab Hospital Public Company Limited and its subsidiaries are as follows:-

Name of Subsidiaries	Type of business	Head office	Percentage of holding (% of share capital)	
			As at September	As at December
			30, 2023	31, 2022
<u>Subsidiaries held directly</u>				
1. Accusfas Lab Center Co., Ltd.	Hospital and clinic	Bangkok	99.99	99.99
2. IMH Bearing Hospital Co., Ltd.	Hospital and clinic	Bangkok	79.99	79.99
3. IMH Silom Hospital Co., Ltd.	Hospital and clinic	Bangkok	99.97	-

			Percentage of holding (% of share capital)	
			As at September	As at December
Name of Subsidiaries	Type of business	Head office	30, 2023	31, 2022
<u>Subsidiaries held indirectly</u>				
1. Suksawat Medical Co., Ltd.	Hospital and clinic	Bangkok	99.99	99.99
2. Mahaesak Hospital Co., Ltd.	Hospital and clinic	Bangkok	79.97	-

On January 31, 2023, the Company acquired 0.01 million shares of IMH Silom Hospital Company Limited at Baht 100 per share, amounting to Baht 1.00 million. As a result, from such shares acquiring, the Company held 99.97 percent of shares in such company which was considered as a new subsidiary. The Company had taken the financial statements of such subsidiary to prepare the consolidated financial statements from the first quarter of 2023 onwards.

On May 31, 2023, the subsidiary had purchased the investment in Mahaesak Hospital Co.,Ltd. for 3.20 million shares, amounted Baht 879.62 million. As a result, from such shares acquiring, the subsidiary had 79.97 percent shareholding in such company that was considered as a subsidiary. The Company had taken the financial statements of such subsidiary to be prepared the consolidated financial statements from May 31, 2023, onwards.

- b) The Company is deemed to have control over an investee or subsidiaries if it has rights, or is exposed, to variable returns from its involvement with the investee, and it has the ability to direct the activities that affect the amount of its returns.
- c) Subsidiaries are fully consolidated, being the date on which the Company obtains control, and continue to be consolidated until the date when such control ceases.
- d) These consolidated financial statements are prepared by including the financial statements of its subsidiaries under control by Intermedical Care And Lab Hospital Public Company Limited after eliminating inter-company transactions between Intermedical Care And Lab Hospital Public Company Limited and its subsidiaries. Investment in the subsidiaries and the shareholders' equity of the subsidiaries has been eliminated from the consolidated financial statements.
- e) Accounting policy for subsidiary company will utilize the same policy as the parent company.
- f) Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent.

- 2.3 The Company prepared the separate interim financial statements which presented investments in subsidiaries under the cost method.

- 2.4 Financial reporting standards that became effective in the current period

During the period, the Company and its subsidiaries have adopted the revised financial reporting standards, which are effective for fiscal years beginning on or after January 1, 2023. This revision is for the financial reporting standards to be clearer and more appropriate and to conform with international financial reporting standards. Such revision does not affect the principles of the standards and does not affect the users of the financial reporting standards.

The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current period.

- 2.5 Revised financial reporting standards to be applied in the future

The Federation of Accounting Professions has announced to apply the revised financial reporting standards 2023 and it was announced in the Royal Gazette on August 8, 2023 on altogether 4 topics: definition of the accounting estimates, disclosure of information of the accounting policy, deferred income tax related to assets and liabilities arising from one transaction and other adjustments due to the change of the Accounting Standard No. 17 "Insurance Contracts". This adjustment is an adjustment for the financial reporting standards to be clearer and more appropriate. This is effective for the financial statements for the accounting period beginning on or after January 1, 2024.

The Management of the Company and its subsidiaries have assessed and believed that this revision will not significantly affect the financial statements in the year that such standard is applied.

3. SIGNIFICANT ACCOUNTING POLICIES

The Company and its subsidiaries prepared the interim financial statement with the same accounting policies used in the preparation of the annual financial statement for year ended December 31, 2022.

4. BUSINESS ACQUISITION

On January 9, 2023, the Company signed an agreement to buy and sell shares of Mahaesak Hospital Co., Ltd., which operated the hospital business in the amount of 3.63 million shares, or 90.77 percent of shares held by existing shareholders. The total amount was Baht 998.42 million. As at the agreement date, the Company had paid a deposit of Baht 30 million for shares. Afterwards, the Company had entered into an additional memorandum of agreement with IMH Silom Hospital Co., Ltd., a subsidiary, as the purchaser of such shares on behalf of the Company.

On May 12, 2023, the Company entered into a memorandum of agreement to amend the agreement to buy and sell shares. The Company agreed to purchase the Company's ordinary shares of Mahaesak Hospital Co., Ltd. in the amount of 3.20 million shares, or 79.97 percent of shareholding, totaling Baht 879.92 million.

Subsequently, on May 31, 2023, the subsidiary had completed the purchase of shares in such company. The subsidiary had paid for the purchase of shares amounted Baht 845.09 million. The balance was payable in cheque amounting to Baht 34.33 million.

This business acquisition was under the condition in accordance with TFRS 3: Business Combinations, which required that identifiable assets, liabilities and contingent liabilities as at the acquisition date were recorded at fair value within the measurement period which had to be not exceed 12 months from the business acquisition date. The subsidiary hired an independent appraiser to determine the fair value of the acquired assets and liabilities from the acquisition date to reflect the results of additional information obtained about the facts and circumstances that existed as at the acquisition date.

For the preparation of the consolidated financial statement for the nine-month period ended September 30, 2023, the Company used net assets value from financial statement as at May 31, 2023 (the acquisition date) of the company and other relevant factors, which may affect such information, as the consideration received from this business acquisition, and measured components of non-controlling interests by considering net assets value according to its proportionate ownership and recorded the difference amount between the purchase price and the value of consideration received in the goodwill.

Details of net assets received and goodwill incurred as at the acquisition date were as follows:

	Baht
Return used in purchase	879,615,000.00
Net assets acquired	29,313,798.29
Goodwill	850,301,201.71

Acquired assets and liabilities as at acquisition date were as follows:

	Baht
Cash and cash equivalents	2,538,558.39
Trade and other current receivables	11,026,903.18
Current contract assets	21,295,101.79
Inventories	3,494,071.92
Other current assets	728,383.98
Restricted bank deposits	1,747,592.82

"UNAUDITED"

"REVIEWED"

- 17 -

	Baht
Land, buildings and equipment	79,649,878.62
Other intangible assets	621,874.39
Deferred income tax assets	1,718,229.51
Other non-current assets	1,007,246.04
Trade and other current payables	(41,865,254.67)
Employee benefit obligations	(7,834,875.91)
Other non-current liabilities	(36,801,926.77)
Net assets	37,325,783.29
<u>Less</u> Non-controlling equity of the subsidiary	(8,011,985.00)
Net assets acquired	29,313,798.29
<u>Add</u> Goodwill	850,301,201.71
Total return used in purchase	879,615,000.00
<u>Less</u> Cash and cash equivalents of the subsidiary	(2,538,558.39)
Undue cheque paid	(34,530,444.44)
Net cash used in business acquisition	842,545,997.17

Therefore, the goodwill as at September 30, 2023 and December 31, 2022 in the consolidated financial statements was as follows:

Name of the company	Baht	
	As at September 30, 2023	As at December 31, 2022
1. Suksawat Medical Co., Ltd.		
By Accufas Lab Center Co., Ltd.	116,258,349.73	116,258,349.73
2. Mahaesak Hospital Co., Ltd.		
By IMH Silom Hospital Co., Ltd.	850,301,201.71	-
	966,559,551.44	116,258,349.73

5. RELATED PARTIES TRANSACTIONS

The Company and its subsidiaries have certain transactions with its related parties. These companies are related through common shareholdings and/or directorships. The effects of these transactions are reflected in the accompanying financial statements on the basis mutual determined by the Company and related parties.

Relationships with related parties that control the Company or are being controlled by the Company or have transactions with the Company/Group are as follows:

Related parties	Nature of relationships
1. Subsidiaries held directly	
1.1 Accufas Lab Center Co., Ltd.	99.99% shareholding
1.2 IMH Bearing Hospital Co., Ltd.	79.99% shareholding
1.3 IMH Silom Hospital Co., Ltd.	99.97% shareholding
2. Subsidiaries held indirectly	
2.1 Suksawat Medical Co., Ltd.	99.99% shareholding
2.2 Mahaesak Hospital Co., Ltd.	79.97% shareholding
3. Related company	
3.1 Ongkharak Hospital	Common Directors
3.2 University of the Thai Chamber of Commerce	Common Directors
3.3 Singha Estate Public Company Limited	Common Directors
3.4 Muang Thai Insurance Public Company Limited	Common Directors
3.5 Capital Plus Advisory Co.,Ltd.	Common Directors
3.6 Siam City Leasing and Factoring Public Company Limited	Common Directors
3.7 Primo Trading Co.,Ltd.	Common Directors
4. Related person	
4.1 Assoc. Prof. Dr.Thanavath Phonvichai	Chairman of the Board
4.2 Mr. Sittiwat Kamkatwong	Director
4.3 Miss Poramaporn Pavarojkit	Director
4.4 Mr. Thibdee Mangkali	Director

The Company had significant business transactions with subsidiary companies, related companies and related persons. Such transactions, which have been concluded on commercial terms and bases agreed upon between the Company, subsidiary companies, related companies and related persons and are in ordinary course of business are summarized below:

5.1 Inter-revenues and expenses

Baht					
Consolidated financial statements			Separate financial statements		Pricing Policy
For the three-month periods ended September 30,			For the three-month periods ended September 30,		
2023	2022		2023	2022	
Inter-transaction with subsidiaries companies (Eliminated from consolidate financial statements)					
Service income	-	-	266,973.31	248,113.80	Mutually agreed price
Office rental income	-	-	-	44,854.11	Contract price
Management income	-	-	-	210,000.00	Mutually agreed price
Interest income	-	-	504,109.58	10,630.14	Market price
Other income	-	-	38,224.00	29,811.00	Mutually agreed price
Interest expense	-	-	154,232.87	-	Market price
Other expenses	-	-	50,000.00	-	Mutually agreed price
Cost of service	-	-	-	484,000.00	Market price
Inter-transaction with related companies					
Advisor fee	-	1,337,500.00	-	1,337,500.00	Contract price
Baht					
Consolidated financial statements			Separate financial statements		Pricing Policy
For the nine-month periods ended September 30,			For the nine-month periods ended September 30,		
2023	2022		2023	2022	
Inter-transaction with subsidiaries companies (Eliminated from consolidate financial statements)					
Service income	-	-	505,594.25	494,293.39	Mutually agreed price
Office rental income	-	-	-	134,562.33	Contract price
Management income	-	-	-	630,000.00	Mutually agreed price
Interest income	-	-	1,364,383.54	53,369.89	Market price
Other income	-	-	61,667.00	11,406,942.84	Mutually agreed price
Interest expense	-	-	154,232.87	-	Market price
Other expenses	-	-	50,000.00	-	Mutually agreed price
Cost of service	-	-	-	2,951,800.00	Market price
Inter-transaction with related companies					
Service income	281,100.00	106,800.00	281,100.00	106,800.00	Mutually agreed price
Financial Advisor fee	-	3,959,000.00	-	2,675,000.00	Contract price

5.2 Inter outstanding

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022
Trade and other current receivables (Note 7)				
Subsidiaries	-	-	19,665,950.39	12,111,383.14
	-	-	19,665,950.39	12,111,383.14

Short-term loans to subsidiary

For the nine-month period ended September 30, 2023, the movement of short-term loans to subsidiary were as follows:

	Baht		
	Separate financial statements		
	As at December	Transaction during the period	
	31, 2022	Increase	Settlement
IMH Bearing Hospital Co., Ltd.	-	40,000,000.00	-
Total	-		40,000,000.00

Such loan was in promissory notes at the interest rate of 5% due at call and without collateral.

Short-term loans from subsidiary

For the nine-month period ended September 30, 2023, the movement of short-term loans to subsidiary were as follows:

	Baht		
	Separate financial statements		
	As at December	Transaction during the period	
	31, 2022	Increase	Payment
Accusfas Lab Center Co., Ltd.	-	20,000,000.00	-
Total	-		20,000,000.00

Such loan was in promissory notes at the interest rate of 5.35 - 5.60% due at call and without collateral.

"UNAUDITED"

"REVIEWED"

- 21 -

Management remuneration

Management remuneration for the three-month periods ended September 30, 2023 and 2022 as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Short-term employee benefits	5,756,300.00	6,300,650.00	2,919,000.00	3,468,000.00
Post-employment benefits	181,930.00	133,822.00	181,930.00	133,822.00
Total	<u>5,938,230.00</u>	<u>6,434,472.00</u>	<u>3,100,930.00</u>	<u>3,601,822.00</u>

Management remuneration for the nine-month periods ended September 30, 2023 and 2022 as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Short-term employee benefits	17,399,183.00	18,675,648.44	8,715,000.00	10,404,000.00
Post-employment benefits	545,789.00	401,467.00	545,789.00	401,467.00
Total	<u>17,944,972.00</u>	<u>19,077,115.44</u>	<u>9,260,789.00</u>	<u>10,805,467.00</u>

6. CASH AND CASH EQUIVALENTS

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September 30, 2023	As at December 31, 2022	As at September 30, 2023	As at December 31, 2022
Cash on hand	1,594,891.25	710,954.00	665,726.25	318,193.00
Cheque on hand	118,139.56	675,601.40	118,139.56	675,601.40
Bank deposits - current accounts	2,652,601.94	14,947,850.19	362,745.28	204,398.02
Bank deposits - saving accounts	39,188,569.78	136,883,783.19	4,793,962.45	95,419,970.73
Bank deposits - fixed	5,175.13	-	-	-
Total	<u>43,559,377.66</u>	<u>153,218,188.78</u>	<u>5,940,573.54</u>	<u>96,618,163.15</u>

Bank deposits - current accounts with credit balance, the Subsidiaries has made an agreement to allow the bank to automatically transfer funds from savings account to such current account, in case of an overdraft.

7. TRADE AND OTHER CURRENT RECEIVABLES

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September 30, 2023	As at December 31, 2022	As at September 30, 2023	As at December 31, 2022
<u>Trade receivables - related parties</u>				
Trade receivables can be classified by age analysis as follows				
Past due less than 3 months	-	-	386,437.85	296,803.24
Past due over 3 months	-	-	378,032.74	-
Total trade receivables - related parties	-	-	764,470.59	296,803.24
<u>Trade receivables - unrelated parties</u>				
Note received	67,075.50	26,160.00	67,075.50	26,160.00
Trade receivables can be classified by age analysis as follows				
Not yet due	34,957,778.45	16,184,864.89	18,770,611.75	15,954,520.59
Past due				
Less than 3 months	13,645,963.51	7,852,546.08	7,808,829.51	5,116,742.08
3 - 6 months	7,453,592.00	1,077,131.00	276,255.00	1,077,131.00
6 - 12 months	847,040.75	175,741.00	279,690.00	68,305.00
Over 12 months	708,102.00	778,462.00	708,102.00	628,462.00
Total	57,679,552.21	26,094,904.97	27,910,563.76	22,871,320.67
<u>Less</u> Allowance for expected credit losses	(3,021,509.64)	(789,532.40)	(989,542.21)	(789,532.40)
Total trade receivables - unrelated parties	54,658,042.57	25,305,372.57	26,921,021.55	22,081,788.27
Total trade receivables - net	54,658,042.57	25,305,372.57	27,685,492.14	22,378,591.51
<u>Other current receivable - related parties</u>				
Other receivables	-	-	18,901,479.80	11,814,579.90
Total other current receivables - related parties	-	-	18,901,479.80	11,814,579.90
<u>Other current receivables - unrelated parties</u>				
Prepaid insurance	439,489.37	396,678.46	350,756.36	337,499.03
Prepaid expenses	688,886.72	243,666.21	114,141.17	68,840.11
Employee loan receivables	655,300.00	665,030.00	655,300.00	665,030.00
Other	284,204.25	345.00	158,826.00	345.00
Total other current receivables - unrelated parties	2,067,880.34	1,305,719.67	1,279,023.53	1,071,714.14
Total other receivables	2,067,880.34	1,305,719.67	20,180,503.33	12,886,294.04
Total trade and other current receivables - net	56,725,922.91	26,611,092.24	47,865,995.47	35,264,885.55

"UNAUDITED"

"REVIEWED"

- 23 -

For the nine-month periods ended September 30, 2023 and 2022, the movement of allowance for expected credit losses were as follows :

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Beginning balance	(789,532.40)	(1,214,591.92)	(789,532.40)	(985,271.62)
Increase from business acquisition	(756,271.66)	-	-	-
(Increase) decrease during the period	(1,475,705.58)	(91,600.85)	(200,009.81)	27,362.83
Write off for the period	-	377,644.80	-	377,644.80
Ending balance	<u>(3,021,509.64)</u>	<u>(928,547.97)</u>	<u>(989,542.21)</u>	<u>(580,263.99)</u>

8. CURRENT CONTRACT ASSETS

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022
Hospital	405,690,015.56	342,835,577.77	-	-
Occupational Medicine Hospital				
Past due less than 12 months	30,982,086.47	37,183,089.81	30,982,086.47	37,183,089.81
Total	436,672,102.03	380,018,667.58	30,982,086.47	37,183,089.81
<u>Less</u> Allowance for expected credit losses	<u>(4,779,026.92)</u>	<u>(4,720,629.67)</u>	<u>(43,570.81)</u>	<u>(92,454.85)</u>
Current contract assets - net	<u>431,893,075.11</u>	<u>375,298,037.91</u>	<u>30,938,515.66</u>	<u>37,090,634.96</u>

For the nine-month periods ended September 30, 2023 and 2022, the movement of allowance for expected credit losses were as follows :

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Beginning balance	(4,720,629.67)	-	(92,454.85)	-
(Add) Less during the period	(58,397.25)	-	48,884.04	-
Ending balance	<u>(4,779,026.92)</u>	<u>-</u>	<u>(43,570.81)</u>	<u>-</u>

Hospital

The current contract assets as the accrued medical treatment income. The management of the subsidiary makes an estimation of accrued income based on the amount of the latest actual collection together with the current circumstances which have the reimbursements in accordance with terms and conditions stipulated by Social Security Office and National Health Security Office Hospital consist of ;

	Baht	
	Consolidated financial statements	
	As at September 30, 2023	As at December 31, 2022
Accrued medical service income 2023	178,239,082.19	-
Accrued medical service income 2022	167,616,921.68	282,632,951.89
Accrued medical service income 2021	59,834,011.69	60,202,625.88
Total	405,690,015.56	342,835,577.77

- 1) On June 18, 2021, the National Health Security Office (NHSO) had issued a notification letter to pay damages in case of the overcharges for health care services or breaching the terms of Metabolic Screening Project agreement. In 2019, the Subsidiaries had made a compromise letter with the National Health Security Office by summarizing the expenses that the Company had to pay and the fund that the National Health Security Office had delayed the payment. The Company expected to receive a total net amounted Baht 15.99 million.
- 2) In 2021, the Subsidiaries recognises revenue OP Refer of the years 2019 - 2021 under E-Claim system of the National Health Security Office. The Subsidiaries has not recognised revenue in the year incurred in the amount of Baht 11.06 million. At present, the Subsidiary not yet received payment.
- 3) On July 12, 2022 the National Health Security Office had a letter informing the transfer of medical service fee (NHSO). The medical service fee deduction is Baht 26.50 Million. The information pertaining to the request to receive the expense recorded through E-claim has not been verified before the compensation payment (data needs verify). On July 19, 2022 the Subsidiaries issued a letter to oppose the result of the data verification on the medical service fee disbursement to NHSO. However, the management has verified the information and proceeded to further notify in E-claim. It is believed that the Subsidiaries will receive back the medical service fee that had been

"UNAUDITED"

"REVIEWED"

- 25 -

deducted. During the year 2023, the subsidiary received payment of Baht 5.84 million. The balance as at September 30, 2023, amount Baht 20.66 million.

9. INVENTORIES

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022
Medical supplies	3,764,403.75	3,716,166.65	2,667,531.05	2,640,885.65
Medicine and Medical supplies	20,975,029.05	10,674,473.16	4,810,202.70	256,983.39
Total	24,739,432.80	14,390,639.81	7,477,733.75	2,897,869.04

10. OTHER CURRENT ASSETS

Consisted of :

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022
Withholding tax deducted at source	7,619,412.06	5,851,529.73	4,669,633.44	4,487,014.71
Deposits	2,559,580.00	3,730,478.00	2,559,580.00	3,730,478.00
Office supplies	2,058,199.97	940,057.12	481,504.06	573,618.14
Total	12,237,192.03	10,522,064.85	7,710,717.50	8,791,110.85

11. INVESTMENTS IN SUBSIDIARIES

Investments in subsidiaries as represented in separate financial statements, as follows:

Name of subsidiaries	Paid up share capital				Separate financial statements	
	(Thousand Baht)		Percentage of shareholding (%)		Cost method (Thousand Baht)	
	As at September	As at December	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022	30, 2023	31, 2022
1. Accusfas Lab Center Co., Ltd.	164,000	164,000	99.99	99.99	164,000	164,000
2. IMH Bearing Hospital Co., Ltd.	1,000	1,000	79.99	79.99	800	800
3. IMH Silom Hospital Co., Ltd.	813,936	-	99.97	-	814,186	-
Total					978,986	164,800

Investment in IMH Silom Hospital Co., Ltd.

On January 26, 2023 the Company invested in the ordinary shares of IMH Silom Co., Ltd., a new established company. Such company has registered capital Baht 1 million. The Company held shares in such company at 99.97 percent of the shares issued and paid up amounted Baht 0.25 million. The shares are called for paid up 25 percent of the registered ordinary shares 10,000 shares at Baht 100 per share. Such company has been registered as company limited with Ministry of Commerce on January 31, 2023. Later on May 31, 2023, the Company had repaid the total shares fee at 75 percent of the ordinary shares.

On May 31, 2023, the Company had invested to purchase the capital increase shares in IMH Silom Hospital Co., Ltd. for 9,999,000 shares amounted Baht 999.00 million. The Company had repaid the total shares fee amounted Baht 813.94 million. The shareholding of the Company in such company was 99.97 percent of the issued and paid-up shares of such company.

Investment in Mahaesak Hospital Co., Ltd.

On May 31, 2023, the subsidiary - IMH Silom Hospital Co., Ltd. had purchased the investment in Mahaesak Hospital Co., Ltd. for 3.20 million shares, amounted Baht 879.62 million. As a result, from such shares acquiring, the subsidiary had 79.97 percent shareholding in such company that was considered as an indirectly subsidiary.

On August 16, 2023 the subsidiary - Mahaesak Hospital Co., Ltd. entered into asset purchase/sale agreement with the subsidiary - IMH Silom Hospital Co., Ltd. which is a company under the same group according to the detail of the shareholding restructure of the company group. The asset purchase price is set to not exceed the book value on the transaction date and the completion date is August 31, 2023. After selling the assets and transferring the hospital operating license (Sor.Por.7) and the personnel of such business from Mahaesak Hospital Co., Ltd. IMH Silom Hospital Co., Ltd. will begin operating the hospital in place of Mahaesak Hospital Co., Ltd. and the management of the subsidiary - Mahaesak Hospital Co., Ltd. is under selection of appropriate business for further operation of the business.

12. PROPERTY, PLANT AND EQUIPMENT

Movements of the property, plant and equipment account for the nine-month period ended September 30, 2023 are summarized as follows:

	Baht	
	Consolidated	Separate
	financial statements	financial statements
At cost		
Balance as at December 31, 2022	374,294,733.21	282,263,459.74
Acquisitions during the period	19,527,641.27	342,144.65
Increase from business acquisition (Note 4)	305,524,873.14	-
Disposals during the period	(3,952,884.03)	-
Balance as at September 30, 2023	695,394,363.59	282,605,604.39
Accumulated depreciation		
Balance as at December 31, 2022	(215,250,526.74)	(153,473,116.56)
Depreciation for the period	(17,596,227.83)	(8,651,928.92)
Increase from business acquisition (Note 4)	(225,874,994.52)	-
Accumulated depreciation on disposals	3,809,726.92	-
Balance as at September 30, 2023	(454,912,022.17)	(162,125,045.48)
Net book value		
Balance as at December 31, 2022	159,044,206.47	128,790,343.18
Balance as at September 30, 2023	240,482,341.42	120,480,558.91

As at September 30, 2023 and December 31, 2022, the Company and its subsidiaries had assets with the depreciation fully calculated but still in use which had a cost value of Baht 350.10 million and Baht 156.47 million, respectively. (Separate: Baht 116.06 million and Baht 106.68 million, respectively).

As at September 30, 2023 and December 31, 2022, part of land with buildings with a book value of Baht 64.27 million and Baht 66.35 million, respectively were used by the Company as collateral for bank overdrafts and long-term loans.

13. RIGHT-OF-USE ASSETS

- 13.1 Movements of the right-of-use assets account during the nine-month period ended September 30, 2023 are summarized below

	Baht	
	Consolidated financial statements	Separate financial statements
Balance as at December 31, 2022	165,063,609.32	12,133,592.67
Increase	1,596,050.00	652,700.00
Depreciation for the period	(9,633,150.94)	(3,659,722.54)
Balance as at September 30, 2023	157,026,508.38	9,126,570.13

- 13.2 The following are the amounts recognized in profit or loss:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Depreciation of right-of-use assets	9,633,150.94	8,880,125.08	3,659,722.54	4,770,648.93
Interest expense on lease liabilities	8,448,666.10	8,005,468.75	370,919.18	553,582.20
Expense relating to short-term lease	47,365.34	1,756,939.99	47,365.34	1,756,939.99
Total	18,129,182.38	18,642,533.82	4,078,007.06	7,081,171.12

For the nine-month periods ended September 30, 2023 and 2022, the total cash outflow for leases on consolidated financial statements amount to Baht 13.49 million and Baht 15.13 million, respectively. On separate financial statement amount to Baht 4.65 million and Baht 8.31 million, respectively.

14. OTHER INTANGIBLE ASSETS

Movements of the other intangible assets account during the nine-month period ended September 30, 2023 are summarized below

	Baht	
	Consolidated financial statements	Separate financial statements
At cost		
Balance as at December 31, 2022	57,988,677.43	8,217,490.65
Acquisitions during the period	402,492.00	-
Increase from business acquisition (Note 4)	8,043,659.10	-
Balance as at September 30, 2023	66,434,828.53	8,217,490.65
Accumulated amortization		
Balance as at December 31, 2022	(9,262,781.00)	(4,473,863.14)
Amortization for the period	(3,103,028.90)	(886,831.99)
Increase from business acquisition (Note 4)	(7,421,784.71)	-
Balance as at September 30, 2023	(19,787,594.61)	(5,360,695.13)
Net book value		
Balance as at December 31, 2022	48,725,896.43	3,743,627.51
Balance as at September 30, 2023	46,647,233.92	2,856,795.52

15. DEFERRED TAX ASSETS AND LIABILITIES

Deferred tax assets and deferred tax liabilities as follows:-

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September 30, 2023	As at December 31, 2022	As at September 30, 2023	As at December 31, 2022
Deferred tax assets	8,527,326.08	5,273,135.77	1,632,309.29	1,348,433.96
Deferred tax liabilities	(5,586,893.94)	(5,577,066.21)	-	-
Deferred tax assets (liabilities) - net	2,940,432.14	(303,930.44)	1,632,309.29	1,348,433.96

Changes in deferred tax assets and liabilities for the nine-month period ended September 30, 2023 are summarized as follows:

Baht					
Consolidated financial statements					
Balance as at	Revenue (expenses) during the period			Balance as at	
December	Increase from	In profit or loss	In other	September	
31, 2022	Business		comprehensive	30, 2023	
	Acquisition		income		
	(Note 4)				
Deferred tax assets :					
Allowance for the expected credit losses	1,102,032.41	151,254.33	306,820.58	-	1,560,107.32
Lease liabilities	4,021,243.80	-	1,024,278.26	-	5,045,522.06
Employee benefit obligations	1,393,229.60	1,566,975.18	305,918.66	-	3,266,123.44
Provisions	331,782.39	-	(331,782.39)	-	-
Deferred subsidies	847,397.80	-	(89,677.38)	-	757,720.42
Total	<u>7,695,686.00</u>	<u>1,718,229.51</u>	<u>1,215,557.73</u>	<u>-</u>	<u>10,629,473.24</u>
Deferred tax liabilities :					
Effect of the business acquisition adjustment	(7,999,616.44)	-	310,575.34	-	(7,689,041.10)
Total	<u>(7,999,616.44)</u>	<u>-</u>	<u>310,575.34</u>	<u>-</u>	<u>(7,689,041.10)</u>
Baht					
Separate financial statements					
Balance as at	Revenue (expenses) during the period			Balance as at	
December	In profit or loss	In other		September	
31, 2022		comprehensive		30, 2023	
		income			
Deferred tax assets :					
Allowance for the expected credit losses	176,397.45	30,225.16	-		206,622.61
Lease liabilities	54,842.31	(11,242.83)	-		43,599.48
Employees benefit obligations	1,117,194.20	264,893.00	-		1,382,087.20
Total	<u>1,348,433.96</u>	<u>283,875.33</u>	<u>-</u>		<u>1,632,309.29</u>

16. TRADE AND OTHER CURRENT PAYABLES

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022
Trade payables - unrelated parties	66,245,542.15	32,539,654.70	12,710,693.92	10,180,806.30
Other current payables - related parties				
Interest expense	-	-	94,397.26	-
Other current payables				
Outstanding cheque - shares payable	36,246,750.00	-	-	-
Accrued expenses	30,423,740.55	11,751,039.31	5,341,222.25	4,559,746.24
Advance payment	384,823.30	293,886.50	362,283.30	136,291.50
Other	18,619,412.23	1,364,103.67	1,179,213.17	1,042,603.67
Total other current payables	85,674,726.08	13,409,029.48	6,977,115.98	5,738,641.41
Total trade and other current payables	151,920,268.23	45,948,684.18	19,687,809.90	15,919,447.71

17. LONG-TERM LOANS FROM FINANCIAL INSTITUTIONS

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022
Ending balance	800,000,000.00	-	800,000,000.00	-
<u>Less</u> : Deferred financial cost	(2,836,206.85)	-	(2,836,206.85)	-
<u>Add</u> : Accrued interest	836,206.85	-	836,206.85	-
	798,000,000.00	-	798,000,000.00	-
<u>Less</u> : Current portion due within 1 year	(105,000,000.00)	-	(105,000,000.00)	-
Long-term loans from financial institutions, net	693,000,000.00	-	693,000,000.00	-

On May 16, 2023, the Company entered into a loan agreement with a local bank amounted Baht 800.00 million to increase capital in IMH Silom Hospital Co., Ltd. (subsidiary). The interest rate in the month No. 1 - 36, charged MLR-1.5 percent per annum and from the month No. 37, charged MLR-1 percent per annum. The repayment was due in 84 monthly installments. The principal was repayable in installments at Baht 10.50 million each. The first installment was started upon the maturity of 7 months from the first

drawdown date. The mortgage of 21 title deeds of land and buildings of the Company and its subsidiaries and certain of the Company's ordinary shares were as collateral for loans.

The loan agreement contained certain covenants and restrictions such as maintaining direct and/or indirect shareholding in the Mahaesak Hospital Co., Ltd. and IMH Silom Hospital Co., Ltd. and maintaining certain financial ratios, etc.

18. LEASE LIABILITIES

The carrying amounts of lease liabilities and the movement for the nine-month period ended September 30, 2023 are presented below

	Baht	
	Consolidated financial statements	Separate financial statements
Book value at beginning balance	172,584,631.05	10,718,043.73
Increase	1,567,550.00	652,700.00
Accretion of interest	8,448,666.10	370,919.18
Payments	(13,445,210.83)	(4,600,140.94)
Book value at ending balance	169,155,636.32	7,141,521.97
<u>Less</u> Current portion due within 1 year	(8,675,939.17)	(5,045,116.91)
Lease liabilities - net	160,479,697.15	2,096,405.06

As at September 30, 2023, the Company and subsidiaries have lease liabilities to be paid as follows:

	Baht					
	Consolidated financial statement			Separate financial statement		
	Principal	Deferred interest	Payment	Principal	Deferred interest	Payment
Current portion due within						
one year	8,675,939.17	8,214,152.16	16,890,091.33	5,045,116.91	232,667.05	5,277,783.96
Current portion due after one						
year not over five years	7,789,496.62	36,879,690.96	44,669,187.58	2,096,405.06	79,332.94	2,175,738.00
Current portion due after						
five years	152,690,200.53	173,717,547.90	326,407,748.43	-	-	-
Total	169,155,636.32	218,811,391.02	387,967,027.34	7,141,521.97	311,999.99	7,453,521.96

19. EMPLOYEE BENEFIT OBLIGATIONS

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022
Employee benefit obligations at beginning balance	6,966,147.99	11,012,964.99	5,585,970.99	8,606,067.99
Gain on re-measurements of defined benefit plans				
From demographic assumption changes	-	(752,586.00)	-	(752,586.00)
From changes in financial assumptions	-	193,247.00	-	193,247.00
From improving the experience	-	(4,983,712.00)	-	(3,700,492.00)
Benefits paid by the plans	-	(152,448.00)	-	(152,448.00)
Increase from business acquisition (Note 4)	7,834,875.91	-	-	-
Current service costs and interest	1,529,593.32	1,648,682.00	1,324,465.00	1,392,182.00
Employee benefit obligations at ending balance	16,330,617.22	6,966,147.99	6,910,435.99	5,585,970.99

Expense recognized in the statements of comprehensive income for the three-month periods ended September 30, 2023 and 2022.

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Current service cost	292,296.99	386,228.00	410,219.00	324,555.00
Interest cost	102,988.75	26,739.00	31,275.00	23,485.00
Total	395,285.74	412,967.00	441,494.00	348,040.00

Expense recognized in the statements of comprehensive income for the nine-month periods ended September 30, 2023 and 2022.

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Current service cost	1,334,357.99	1,158,644.00	1,230,640.00	973,680.00
Interest cost	195,235.33	80,217.00	93,825.00	70,455.00
Total	1,529,593.32	1,238,861.00	1,324,465.00	1,044,135.00

20. OTHER NON-CURRENT PROVISIONS

In 2021, the subsidiaries - Mahaesak Hospital Co., Ltd. had been notified the results of the examination of the use of medical services in the case of high-cost diseases in 2015 and 2016 by the random data checking for medical services from the Social Security Office. The Social Security Office had found the incorrect percentage of AdjRW from the amount that the hospital should receive. But the subsidiaries were able to proceed with the dispute according to the period specified by the Social Security Office. However, the subsidiaries expected that the medical service fees would be refunded from the Social Security Office from information and past experience in the total amount of Baht 4.55 million.

In 2022, the subsidiaries - Mahaesak Hospital Co., Ltd. had been notified the results of the examination of the use of medical services in the case of high-cost diseases in 2019 by the random data checking for medical services from the Social Security Office. The Social Security Office had found the incorrect percentage of AdjRW from the amount that the hospital should receive. But the subsidiaries were able to proceed with the dispute according to the period specified by the Social Security Office. However, the subsidiaries expected that the medical service fees would be refunded from the Social Security Office from information and past experience in the total amount of Baht 12.59 million.

The Social Security Office had notified by the letter informing the results of the examination of the use of medical services in the case of high-cost diseases in 2018 and 2020 - 2021 by the random data checking for medical services. The Social Security Office had found the incorrect percentage of AdjRW from the amount that the hospital should receive. But the subsidiaries - Mahaesak Hospital Co., Ltd. were able to proceed with the dispute according to the period specified by the Social Security Office. However, the Company and its subsidiaries expected that the medical service fees would be refunded from the Social Security Office from information and past experience in total Baht 19.66 million.

As at September 30, 2023 the Company and its subsidiaries had other non-current provisions in the amount of Baht 36.80 million in the statements of financial position.

21. TREASURY SHARES

At the Board of Directors' Meeting No. 5/2021 held on August 30, 2021, it had the resolution to approve the Treasury Stock Project to manage excess liquidity of the Company, within the limit of not more than 50 million baht, the number of shares to be repurchased not more than 3 million shares, or equivalent to not more than 1.4 percent of the total issued shares. The repurchasing period in the Stock Exchange of Thailand is between September 14, 2021 to March 11, 2022, which have to be resold the shares held in treasury within 3 years after the completion date, which is the day the company has

completely purchased shares as stated in the project or 6 months after the implementation, whichever is the earlier. If the company cannot sell off all repurchased shares at the time, then it should write off the remaining repurchased amount. The treasury stock held by the Company will not be counted as a quorum of shareholders and will not have the right to vote and the right to receive dividends.

When the share capital is repurchased, the amount of consideration paid including directly attributable costs, is classified as treasury stock and presented as a deduction in shareholders' equity and the same amount is allocated from retained earnings to treasury stock reserve under shareholders' equity. When reselling treasury stock, the amount is recognized as an increase in shareholders' equity by debit the treasury stock the cost of treasury stock sold calculated by the weighted average method, and transferring the same amount from the treasury shares reserve account to retained earnings. The surplus on the resale of treasury stock is presented as a separate item in shareholders' equity. Net loss on sale or cancellation of treasury stock is deducted from retained earnings after deducting all surplus on treasury share.

As at March 11, 2022 (date of completion of the share repurchase period), the Company had purchased back 1,000,000 ordinary shares (par value of Baht 0.50 each), or 0.47% of total number of issued and fully shares, for a total of Baht 13,286,810 (excluded cost of repurchase treasury shares).

The Board of Directors' Meeting No. 3/2022 held on August 10, 2022 had a resolution to approve the sale of repurchased shares by offering on the Stock Exchange of Thailand between September 12, 2022 and February 13, 2023 at the offering repurchased price not less than the average closing price of IMH shares over the last five trading days less 15 percent of such average closing price.

On January 22, 2023, the Board of Directors' Meeting had a resolution to cancel the sale of shares during that period and would inform again three days in advance before proceeding the sale.

The movement of treasury shares for the nine-month period ended September 30, 2023 is as follows:

	Consolidated / Separate financial statements	
	Number of shares	Amount of treasury shares (Baht)
Balance as at January 1, 2023	1,000,000	13,286,810.00
Reissuance during the period (Baht 13.60 per share)	(1,800)	(23,922.00)
Balance as at September 30, 2023	998,200	13,262,888.00

During the year 2023, the Company reissuance 1,800 treasury shares at the price of Baht 13.60 per share, totalling Baht 24,480.00 and resulted in a surplus on treasury stock of Baht 558.00

As at September 30, 2023, all the repurchased shares have not been registered for capital reduction and are still held as treasury shares waiting for reissuance.

22. DIVIDEND

According to the Annual General Shareholders' Meeting of the Company for the year 2023 dated April 29, 2023, it had a resolution to approve the dividend payment from the annual retained earnings to 213,293,900 ordinary shares (or equal to the number of ordinary shares of the Company issued and paid-up for 215,000,000 shares less by all repurchase shares and shares that are not entitled to receive dividend of 1,706,100 shares from the project due date on March 11, 2022) at Baht 0.14 each, amounted Baht 29.86 million. The dividend had been paid on May 25, 2023.

23. (INCOME) TAX EXPENSES

Major components of (income) tax expenses for the three-month periods ended September 30, 2023 and 2022 consisted of

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
(Income) tax expenses shown in profit or loss:				
Current income tax:				
Income tax expenses for the period	2,152,695.22	9,801,973.31	(1,047,012.83)	2,805,249.25
Deferred (income) tax expenses:				
Changes in temporary differences relating to the original recognition and reversal	(672,102.57)	63,339.61	(104,678.56)	152,703.11
Total	<u>1,480,592.65</u>	<u>9,865,312.92</u>	<u>(1,151,691.39)</u>	<u>2,957,952.36</u>

Major components of (income) tax expenses for the nine-month periods ended September 30, 2023 and 2022 consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
(Income) tax expenses shown in profit or loss:				
Current income tax:				
Income tax expense for the period	19,474,236.54	55,458,804.94	-	2,805,249.25
Deferred (income) tax expenses:				
Changes in temporary differences relating to the original recognition and reversal	(1,526,133.07)	(3,423,838.98)	(283,875.33)	(46,439.29)

"UNAUDITED"

"REVIEWED"

- 37 -

Total	<u>17,948,103.47</u>	<u>52,034,965.96</u>	<u>(283,875.33)</u>	<u>2,758,809.96</u>
Income tax relating to components of other comprehensive income:				
Deferred tax relation to:				
Gains on re-measurements of defined benefit plans	-	468,716.20	-	244,931.80
Total	<u>-</u>	<u>468,716.20</u>	<u>-</u>	<u>244,931.80</u>

24. BASIC EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is calculated by dividing the profit (loss) for the period attributable to shareholders of the Company (excluded other comprehensive income) by the weighted average number of ordinary shares which are issued and paid-up during the period.

For the three-month and nine-month periods ended September 30, 2023 and 2022

	Consolidated financial statements			
	For the three-month periods		For the nine-month periods	
	ended September 30,		ended September 30,	
	2023	2022	2023	2022
Profit attributable to ordinary				
Owners of the company (Baht)	(18,339,407.17)	40,754,032.10	41,180,836.26	219,890,640.92
Weighted average number of ordinary shares (Shares)	214,001,800	214,000,000	214,001,688	214,000,000
Basic earnings per share (Baht per shares)	(0.09)	0.19	0.19	1.03
	Separate financial statements			
	For the three-month periods		For the nine-month periods	
	ended September 30,		ended September 30,	
	2023	2022	2023	2022
Profit (loss) attributable to ordinary				
Owners of the company (Baht)	(30,053,842.21)	11,232,081.39	(27,407,017.55)	9,028,767.58
Weighted average number of ordinary shares (Shares)	214,001,800	214,000,000	214,001,688	214,000,000
Basic earnings (loss) per share (Baht per shares)	(0.14)	0.05	(0.13)	0.04

25. OPERATING SEGMENT

Operating segment information is reported in a manner consistent with the internal reports that are regularly reviewed by the chief operating decision maker in order to make decisions about the allocation of resources to the segment and assess its performance. The chief operating decision maker has been identified as the executive committee.

The Company and its subsidiaries's main businesses were specialized occupational medicine hospital, medical services, analyzed samples and sent for medical diagnosis. Its operations are carried on

only in Thailand. Segment performance is measured based on operating profit or loss, on a basis consistent with that used to measure operating profit or loss in the financial statements.

From October 2022 onwards, the management of the Company and its subsidiaries have an opinion to stop the environmental analysis operations under the management of Accusfas Lab Center Co., Ltd. in order for the Company to fully focus on operating the hospital business.

	Thousand Baht							
	Consolidated statements of comprehensive income (partial) for the three-month periods ended September 30,							
	Hospital		Occupational Medicine		Environmental analysis		Total	
	Hospital							
	2023	2022	2023	2022	2023	2022	2023	2022
Revenue from business	138,046	88,392	31,571	59,918	-	13	169,617	148,323
Cost of business	(100,685)	(43,819)	(27,778)	(30,128)	-	(336)	(128,463)	(74,283)
Gross profit (loss)	37,361	44,573	3,793	29,790	-	(323)	41,154	74,040
Other incomes							1,222	3,826
Selling expenses							(3,867)	(2,965)
Administrative expenses							(40,958)	(21,642)
Finance costs							(13,486)	(2,646)
(Income) tax expenses							(1,480)	(9,865)
Profit for the period							(17,415)	40,748
<u>Segment revenues from service</u>								
At point in time	138,046	88,392	31,571	59,918	-	13	169,617	148,323
Total	138,046	88,392	31,571	59,918	-	13	169,617	148,323

	Thousand Baht							
	Consolidated statements of comprehensive income (partial) for the nine-month periods ended September 30,							
	Hospital		Occupational Medicine		Environmental analysis		Total	
	Hospital							
	2023	2022	2023	2022	2023	2022	2023	2022
Revenue from business	344,001	440,388	111,484	142,482	-	89	455,485	582,959
Cost of business	(207,226)	(137,348)	(65,913)	(87,487)	-	(1,519)	(273,139)	(226,354)
Gross profit (loss)	136,775	303,040	45,571	54,995	-	(1,430)	182,346	356,605
Other incomes							4,735	10,845
Selling expenses							(12,453)	(16,975)
Administrative expenses							(92,100)	(70,495)
Finance costs							(22,513)	(8,060)
(Income) tax expenses							(17,948)	(52,035)
Profit for the period							42,067	219,885

<u>Segment revenues from service</u>								
At point in time	344,001	440,388	111,484	142,482	-	89	455,485	582,959
Total	<u>344,001</u>	<u>440,388</u>	<u>111,484</u>	<u>142,482</u>	<u>-</u>	<u>89</u>	<u>455,485</u>	<u>582,959</u>
<u>Assets as at September 30,</u>								
Fixed assets	120,002	27,132	120,480	131,786	-	893	240,482	159,811
Other assets	665,581	624,605	1,139,470	354,786	-	7,563	1,805,051	986,954
Total	<u>785,583</u>	<u>651,737</u>	<u>1,259,950</u>	<u>486,572</u>	<u>-</u>	<u>8,456</u>	<u>2,045,533</u>	<u>1,146,765</u>

Information about major customers

For the nine-month period ended September 30, 2023, the Company and its subsidiaries had revenue from 4 major customers, total amount Baht 216.14 million equivalent to 47.45 percent of operating income.

For the nine-month period ended September 30, 2022, the Company and its subsidiaries had revenue from 4 major customers, total amount Baht 247.22 million equivalent to 42.41 percent of operating income.

26. COMMITMENTS AND CONTINGENT LIABILITIES

As at September 30, 2023 and December 31, 2022, the Company and its subsidiaries have commitments and contingent liabilities as follows:

26.1 Capital commitments

The Company and its subsidiaries had capital commitments relating to be paid as follows:

	Million Baht			
	Consolidated financial statements		Separate financial statements	
	As at September 30, 2023	As at December 31, 2022	As at September 30, 2023	As at December 31, 2022
Construction of buildings	41.03	1.29	-	-
The medical instruments	0.78	0.78	0.78	0.78
Installation of the information system	0.51	0.67	0.51	0.51

26.2 Commitment related to land lease agreement

On September 28, 2022, the subsidiary (lessee) entered into the land lease agreement for 30 years with third parties to use for operating the main business related to hospitals and other businesses. according to the purpose of the lessee. It had determined the start date of the rental was the lease registration date at the Land Office by registering the right to lease the property at the Land Office on January 31, 2023. It had a period from January 31, 2023 to January 31, 2053, with the following details of payment of rent:

1. Land leasing fee totaled Baht 133,961,316.75, the lessee agreed to pay the land leasing fee to the lessee under the periods as follows:

Installment	Land leasing fee in Bangkok area (Baht)	Land leasing fee in Samutprakarn area (Baht)	Total land leasing fee (Baht)	Due date
1	27,934,714.38	2,065,285.62	30,000,000.00	Lease registration date
2	13,644,964.74	1,008,807.51	14,653,772.25	Lease registration due date for 1 year or within 30 days from the first day that IMH received the capital from IPO and/or private placement whichever the date was due.
3	41,579,679.12	3,074,093.13	44,653,772.25	Lease registration due date for 2 years
4	41,579,679.12	3,074,093.13	44,653,772.25	Lease registration due date for 3 years

2. The lessee agreed to pay the rent annually starting in Year 4 of the rent at starting price Baht 10,080,000.00 per annum and had to adjust the rental for 5 percent every 5 years from the Year 6 throughout the 30 years agreement according to the land rental rate as follows:

Year	Rental rate per year in Bangkok area (Baht)	Rental rate per year in Samutprakarn area (Baht)	Total rental rate per year (Baht)
1 - 3	None		
4 - 5	9,386,064.03	693,935.97	10,080,000.00
6 - 10	9,855,367.23	728,632.77	10,584,000.00
11 - 15	10,348,135.59	765,064.41	11,113,200.00
16 - 20	10,865,542.37	803,317.63	11,668,860.00
21 - 25	11,408,819.49	843,483.51	12,252,303.00
26 - 30	11,979,260.47	885,657.68	12,864,918.15
Total	291,057,753.81	21,518,651.94	312,576,405.75

Subsequently, on March 1, 2023, the subsidiaries and the lessor entered into a memorandum attached to the land lease agreement for 30 years dated September 28, 2022, as part of the land lease agreement by making an agreement that the lessee intended to begin to occupy and made use to build the buildings in the leased property according to the land lease agreement from January 1, 2024, onwards. The lessor agreed to cooperate and facilitating the issuance of a consent letter allowed to the lessee which the parties agreed as January 1, 2024 as the start date of the lease and the end date of the

lease is January 31, 2053. Other terms and conditions were adhered to and complied with the land lease agreement and the registered lease agreement in all respects.

During the year 2023, the Company had repaid the first installment of the land leasing fee amounted Baht 30 million. The remaining obligation to pay the land leasing fee amounted Baht 103.96 million and the obligation to pay the rent amounted Baht 312.58 million. The obligations related to land lease agreements totaled Baht 416.54 million.

26.3 Commitment related to investment in subsidiaries

The Company had the commitments in investment in two subsidiaries totaled Baht 1,998.42 million and paid the share fees totaled Baht 1,693.81 million. As at September 30, 2023, the Company had the commitment for the unpaid share fees totaled Baht 304.61 million.

26.4 Commitments related to operating agreements

The Company and its subsidiaries have entered into several operating lease agreements in respect of the lease of vehicle, and equipment for operations. The terms of the agreements are generally between 1 and 5 years.

Future minimum lease payments required under these agreements were as follows.

Million Baht				
	Consolidated financial statements		Separate financial statements	
	As at September	As at December	As at September	As at December
	30, 2023	31, 2022	30, 2023	31, 2022
Payable:				
In up to one year	0.62	0.15	0.10	0.12
In over one year and up to five years	1.07	0.08	-	-

26.5 Lawsuit

Subsidiaries

On December 23, 2020, Suksawat Medical Co., Ltd. was sued in a civil lawsuit against service user for breach of medical treatment contract, claim for damages. The amount Baht 21.28 million with interest at the rate of 7.5 percent per annum from the day after of filing day until the payment is completed to the plaintiff. On February 21, 2023, both parties can agree by agreeing to compensate

the plaintiff in the amount of Baht 1.20 million, divided into a subsidiary in the amount of Baht 0.20 million and the 2nd and 3rd defendants in the amount of Baht 1.00 million. The subsidiary has already recorded expenses and provisions of Baht 0.20 million in the financial statements and in 2023, the subsidiary had fully repaid.

On September 16, 2023, Suksawat Medical Co., Ltd. was sued as a civil case by a service user for breach of medical treatment contract, violation, and demanding damages. The amount of capital is 2.60 million baht with interest at the rate of 5 percent per year on the principal from the day following the filing date onwards until payment is made to the plaintiff. Currently, the case is in the process of mediation and witness examination.

26.6 Contingent liabilities

As of September 30, 2023 and December 31, 2022, the Subsidiaries has contingent liabilities from the NHSO in connection with the examination of documents and evidence of expense collection, the total amount is Baht 1.70 million with collateral being accrued income from the NHSO.

26.7 Guarantees

As at September 30, 2023 and December 31, 2022, there were outstanding bank guarantees issued by the banks on behalf of the Company in respect of certain performance bonds as required in the normal course of business. The details of the letters of bank guarantee are as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	As at September 30, 2023	As at December 31, 2022	As at September 30, 2023	As at December 31, 2022
Social Security Office	8,100,000.00	4,000,000.00	-	-
National Health Security Office	3,416,800.00	3,206,800.00	3,206,800.00	3,206,800.00
Guarantees for Influenza vaccine	3,000,000.00	3,000,000.00	3,000,000.00	3,000,000.00
Utility guarantees	1,241,750.00	159,250.00	159,250.00	159,250.00
Others	500,000.00	500,000.00	500,000.00	500,000.00
Total	16,258,550.00	10,866,050.00	6,866,050.00	6,866,050.00

27. FINANCIAL INSTRUMENTS

Fair value of financial instruments

Since the majority of the Group financial instruments are short-term in nature on carry interest at rates close to the market interest rates, their fair value is not expected to be materially different from the amounts presented in the statement of financial position.

28. RECLASSIFICATION

Certain accounts in the 2022 financial statements have been reclassified to conform to the current year's classification, without any effect to the previously reported profit (loss) or shareholder's equity. The reclassifications are as follow:

	Baht		
	Consolidated financial statements		
	Before	Reclassification	After
	Reclassification	Increase (decrease)	Reclassification
<u>Statement of financial position</u>			
Other current assets	9,582,007.73	940,057.12	10,522,064.85
Inventories	15,330,696.93	(940,057.12)	14,390,639.81
	Baht		
	Separate financial statements		
	Before	Reclassification	After
	Reclassification	Increase (decrease)	Reclassification
<u>Statement of financial position</u>			
Other current assets	8,217,492.71	573,618.14	8,791,110.85
Inventories	3,471,487.18	(573,618.14)	2,897,869.04

29. APPROVAL OF INTERIM FINANCIAL STATEMENTS

These interim financial statements were authorized for issue by the Company's Board of directors on November 13, 2023.